ado-trastuzumab emtansine

DRUG8 trials

Conditions

Advanced CancerBladder CancerBone MetastasesBreast CancerColorectal CancerEsophageal CancerGastric CancerHER2 Positive Breast Carcinoma

Phase 1

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

CompletedNCT02038010

Northwestern UniversityHER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer +3

Start: 2014-05-21End: 2017-05-20Updated: 2020-06-29

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

TerminatedNCT02318901

Western Regional Medical CenterAdvanced Cancer, Breast Cancer, Colorectal Cancer +2

Start: 2014-10-31End: 2018-08-31Updated: 2019-10-21

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

CompletedNCT03364348

George W. Sledge Jr.HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer +4

Start: 2017-10-30End: 2022-02-14Updated: 2022-10-19

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

TerminatedNCT04296942

National Cancer Institute (NCI)Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer +2

Start: 2021-05-04End: 2021-10-22Updated: 2022-01-11

Phase 2

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

CompletedNCT01494662

Dana-Farber Cancer InstituteBreast Cancer

Start: 2012-02-01End: 2024-04-19Updated: 2026-01-23

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Active, not recruitingNCT02675829

Memorial Sloan Kettering Cancer CenterBladder Cancer, Lung Cancer, Solid Tumor Cancers +1

Start: 2016-02-01End: 2027-02-01Updated: 2026-03-04

Unknown Phase

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

CompletedNCT00833963

Genentech, Inc.Breast Cancer, Pregnancy

Start: 2009-01-14End: 2017-04-13Updated: 2019-05-16

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Active, not recruitingNCT02226276

City of Hope Medical CenterBone Metastases, HER2-positive Breast Cancer, Liver Metastases +4

Start: 2015-01-07End: 2026-09-29Updated: 2026-02-13

Clinical Cancer Research2025-06-13

A phase 2 basket trial of ado-trastuzumab emtansine for patients with HER2 amplified cancers.

Journal of Clinical Oncology2025-05-28

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.

2024-09-094 citations

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations

Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

Journal of Clinical Oncology2023-06-017 citations

Phase <scp>II</scp> study (<scp>KAMELEON</scp>) of single‐agent <scp>T‐DM1</scp> in patients with <scp>HER2</scp>‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

Cancer Medicine2023-04-2947 citations

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer

Journal for ImmunoTherapy of Cancer2021-09-0136 citations

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Frontiers in Oncology2021-03-0521 citations

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Journal of Clinical Oncology2020-07-17586 citations

Abstract P2-20-01: Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer (MBC): Findings from the NALA, NEfERT-T, and TBCRC 022 trials

Cancer Research2020-02-156 citations

Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine

JCO Precision Oncology2019-10-1738 citations

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

2019-08-2221 citations

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES

Neuro-Oncology Advances2019-08-013 citations

Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases

Cancer Research2019-07-014 citations

Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases

Experimental and Molecular Therapeutics2019-07-01

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.

Journal of Clinical Oncology2019-05-2068 citations

A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

Journal of Clinical Oncology2018-05-2052 citations

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

Journal of Clinical Oncology2017-05-2036 citations

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.

Journal of Clinical Oncology2017-05-2017 citations

Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy.

Journal of Clinical Oncology2017-05-2016 citations

5 more papers not shown

ado-trastuzumab emtansine

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase

Related Papers